A Case of Tamoxifen Keratopathy | Cornea | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Sign In
Clinicopathologic Reports, Case Reports, and Small Case Series
July 2006

A Case of Tamoxifen Keratopathy

Arch Ophthalmol. 2006;124(7):1046-1048. doi:10.1001/archopht.124.7.1046

Tamoxifen citrate (ICI46474) is an antiestrogenic agent1 used in cases of disseminated breast carcinomas and as adjuvant postoperative therapy. Toxic reactions to tamoxifen, such as decreased visual acuity, bilateral macular edema, and yellow-white dots in the paramacular and foveal areas, are relatively rare (reported incidence between 0.9%-12%2,3).

In 1978, Kaiser-Kupfer and Lippman4 first reported the occurrence of what has become known as tamoxifen keratopathy and tamoxifen retinopathy in 4 women treated with very high doses (up to 320 mg per day) of tamoxifen citrate for longer than 1 year. The typical findings were bilateral white, whorl-like, central, subepithelial opacities in the cornea. They also found white refractive opacities superficial to retinal blood vessels, forming clusters located in the paramacular and foveal areas, with the highest concentration temporally, and clinical and angiographic evidence of cystoid macular edema.4 The keratopathy led to decreased visual acuity but was reversible on withdrawal of the drug, whereas the retinopathy, which also led to decreased visual acuity, was not reversible.2,3 Despite the decrease in the recommended dose of tamoxifen, retinopathy was reported in patients taking 40 mg of tamoxifen citrate per day and later in patients taking 20 mg of tamoxifen citrate per day. In the majority of cases, however, the toxic effects were reversible.2 Optic neuritis after tamoxifen use was reported as well.5

Report of a Case

A 74-year-old female patient was referred to Kochi Medical School Hospital in March 2005 for further evaluation of a corneal abnormality by a local ophthalmologist. She complained of decreased vision in both eyes during 1 year. Her medical history was significant. In January 1982, she underwent a local buckling for rhegmatogenous retinal detachment in her right eye. She last visited the ophthalmologist in October 1988 and her best-corrected visual acuity was 0.9 OD and 1.5 OS. No retinal detachment was found, but she was diagnosed with an epiretinal membrane in her right eye. In March 2000, she underwent a partial mammectomy for breast cancer and was treated with 20 mg of tamoxifen citrate (Nolvadex D [delayed release]) daily for 5 years (total dose, 36.5 g). The patient was not taking other medications. She stopped taking tamoxifen in March 2005. Her complaints of visual disturbance in both eyes first appeared after 4 years of tamoxifen treatment, and the corneal abnormality was first found at the same time.

On initial examination, visual acuity was 0.7 OD and 1.2 OS. Intraocular pressure was 18 mm Hg in the right eye and 13 mm Hg in the left eye. Slitlamp examination revealed bilateral whorl-like, subepithelial, crystallin-like opacities of different (green, blue, red, white) colors in the corneas of both eyes (Figure 1). Small, relatively clear zones in the paracentral cornea did not contain deposits. The pattern and location of opacities were similar in both eyes. The corneal endothelium was not clearly seen, and therefore, specular microscopy was performed through the relatively clear paracentral zone. Findings were normal for both eyes. The right eye endothelial cell density was 3100, and the left eye endothelial cell density was 3516. Under local anesthesia, a biopsy of the cornea at the limbal area at the 12-o’clock position was performed and the sample was studied using a transmission electron microscope. Foci of electron-dense, granular deposits were observed in the perinuclear areas of the basal cells. These deposits were present mainly in the basal cells of the limbus and resulted in the atrophic and degenerative changes, such as extension of the cellular processes of the subepithelial matrix, and the decreased height of the basal cells. They were closely adjacent to nuclear envelopes. Some of the deposits resembled lipofuscin (Figure 2).

Figure 1 
A and B, Slitlamp external photograph of the right eye shows subepithelial crystallin-like substance deposition in the cornea.

A and B, Slitlamp external photograph of the right eye shows subepithelial crystallin-like substance deposition in the cornea.

Figure 2 
Transmission electron microscopy showed foci of electron-dense, granular substances in the perinuclear areas of the basal cells (arrows). Some deposits resemble lipofuscin (arrowhead). Bar = 1 μm.

Transmission electron microscopy showed foci of electron-dense, granular substances in the perinuclear areas of the basal cells (arrows). Some deposits resemble lipofuscin (arrowhead). Bar = 1 μm.

According to ophthalmological examination findings and the patient's history of tamoxifen use, she was diagnosed as having a tamoxifen keratopathy, and observation every 2 months was recommended. No special treatment for tamoxifen keratopathy has been prescribed so far because the keratopathy is believed to be reversible.

Tamoxifen retinopathy has also been reported as an adverse effect of tamoxifen administration4; therefore, the patient underwent special examinations. An epiretinal membrane was diagnosed in the patient's right eye during fundus examination. No crystallin-like deposits or macular edema were found in either eye. Because of corneal opacities, the fundus photographs by fluorescence angiography were hazy but revealed normal fluorescence, no apparent retinal pigment epitheliopathy, and no dye leakage from retinal vessels or optic discs in either eye. The electroretinogram revealed decreased amplitude of the b wave, with normal oscillatory potentials. Thus, no evidence of tamoxifen retinopathy was found.

Seven months after initial examination, her best-corrected visual acuity was 0.8 OD and 0.7 OS. The distribution of corneal opacities remained unchanged. The decrease of visual acuity from the time of the initial examination is difficult to explain because there are no conclusive findings supporting this observation. We speculate that this may be due to the gradual progress of keratopathy, especially in the pupillary zone.


Documentation of tamoxifen keratopathy is of big interest, because tamoxifen is a drug used for treatment of disseminated breast carcinomas. The therapy is essential for the patient's chance of survival. Although its incidence is rare and similar aspects can be found in other disorders, the diagnosis of this keratopathy is not difficult if a careful history is taken and good ophthalmological examination is performed.

Corneal changes similar to those described in patients taking tamoxifen have also been reported in asymptomatic carriers of Fabry disease (Anderson-Fabry disease). Cornea verticillata, a whorl-like opacity, has become one of the hallmarks of Fabry disease.6

Corneal deposits were also reported with other antitumor drugs, such as carmustine, in the form of white perilimbal stromal infiltrates, and tilorone hydrochloride, where an increase in the density of the subepithelial opacities, whorl-like clouding of the epithelium, and diffuse and subtle clouding in the epithelium and anterior stroma were found.1

The structure of tamoxifen is similar to other cationic amphiphilic drugs known to produce a retinopathy and keratopathy, including chloroquine, chlorpromazine, thioridazine, and amiodarone hydrochloride.7 Cases of chloroquine8 and amiodarone9 keratopathies have been reported, but, to our knowledge, histopathological features of tamoxifen-induced keratopathy have not been presented to date.

Systemic medications reach the cornea via the tear film, aqueous humor, and limbal vasculature. Amphiphilic medications may produce a drug-induced lipidosis and development of a vortex keratopathy. Corneal changes may result in reduced visual acuity, photophobia, and ocular irritation, which resolve following drug cessation. Corneal manifestations of systemic medications are often dose related.10

After tamoxifen withdrawal, almost all ocular abnormalities were found to be reversible, except for the retinal opacities.3 The question remains whether and when patients taking tamoxifen should be systematically examined by an ophthalmologist. An ophthalmological assessment in case of visual complaints for patients taking tamoxifen remains useful, although routine screening seems to be unnecessary.

Correspondence: Dr Zinchuk, Kochi Medical School, Kohasu, Okoh-cho, Nankoku, Kochi 783-8505, Japan (olga@kochi-ms.ac.jp).

Financial Disclosure: None reported.

Author Contributions: All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Costa  RHMDhooge  MRPVan Wing  FDe Rouck  AF Tamoxifen retinopathy: a case report.  Bull Soc Belge Ophtalmol 1990;238161- 168PubMedGoogle Scholar
Noureddin  BNSeoud  MBashshur  ZSalem  ZShamseddin  AKhalil  A Ocular toxicity in low-dose tamoxifen: a prospective study.  Eye 1999;13729- 733PubMedGoogle ScholarCrossref
Pavlidis  NAPetris  CBriassoulis  E  et al.  Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity: a prospective study of 63 patients.  Cancer 1992;692961- 2964PubMedGoogle ScholarCrossref
Kaiser-Kupfer  MILippman  ME Tamoxifen retinopathy.  Cancer Treat Rep 1978;62315- 320PubMedGoogle Scholar
Pugesgaard  Tvon Eyben  FE Bilateral optic neuritis evolved during tamoxifen treatment.  Cancer 1986;58383- 386PubMedGoogle ScholarCrossref
Nguyen  TTGin  TNicholls  KLow  MGalanos  JCrawford  A Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre.  Clin Experiment Ophthalmol 2005;33164- 168PubMedGoogle ScholarCrossref
Imperia  PSLazarus  HMLass  JH Ocular complications of systemic cancer chemotherapy.  Surv Ophthalmol 1989;34209- 230PubMedGoogle ScholarCrossref
Slowik  CSomodi  Svon Gruben  CRichter  AGuthoff  R Detection of morphological corneal changes caused by chloroquine therapy using confocal in vivo microscopy.  Ophthalmologe 1997;94147- 151PubMedGoogle ScholarCrossref
D'Amico  DJKenyon  KRRuskin  JN Amiodarone keratopathy: drug-induced lipid storage disease.  Arch Ophthalmol 1981;99257- 261PubMedGoogle ScholarCrossref
Hollander  DAAldave  AJ Drug-induced corneal complications.  Curr Opin Ophthalmol 2004;15541- 548PubMedGoogle ScholarCrossref